FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W165943537> ?p ?o ?g. }

• W165943537 endingPage "234" @default.
• W165943537 startingPage "229" @default.
• W165943537 abstract "Purpose Some evidence implicates a role of hydroxychloroquine (HQ) in the management of Sjogren's syndrome. This study evaluated the effect of HQ on saliva B-cell activating factor (BAFF) levels as well as health related quality of life (QoL) in patients with primary Sjogren's syndrome (pSS). Materials and methods Ten pSS patients who had been treated with HQ for at least 2 years and 15 healthy controls (HC) were included in the study. First, HQ was withdrawn for 12 weeks, then baseline evaluation was performed. Subsequently, HQ was restarted and further evaluations were carried out after 12 and 24 weeks of HQ treatment. Oral infection foci were eliminated by dental and periodontal treatments in both groups before enrollment. BAFF levels were evaluated with ELISA in serum and unstimulated mixed saliva. Salivary flow rates of patients and the control group were measured as well. Oral health quality of life (QoL) was evaluated by an oral health impact profile-14 (OHIP-14) questionnaire. Results Salivary BAFF levels (median: 12.39 ng/ml) were significantly decreased by using HQ both at 12 (2.78 ng/ml, P = 0.008) and 24 weeks (0.54 ng/ml, P = 0.011). Similarly, decreases in serum BAFF levels (5.23 ng/ml) were seen at 12 and 24 weeks after HQ treatment (2.18 ng/ml, P = 0.008 and 0.0 ng/ml, P = 0.012, respectively). Serum and salivary BAFF levels were significantly lower in healthy controls (0.37 ng/ml and 0.0 ng/ml, resp.) compared to those of pSS before HQ therapy (P = 0.006 and P = 0.001, resp.). Unstimulated salivary flows were similar in patients treated with HQ after 12 (0.38 ml/min) and 24 weeks (0.50 ml/min) (P = 0.51) but higher than the patients' rate at baseline (0.04 ml/min) (P = 0.008). Conclusion Salivary and serum BAFF levels were lowered in patients with pSS when treated with HQ. In addition, decreased disease activity and increased salivary flows can be achieved with HQ in pSS patients." @default.
• W165943537 created "2016-06-24" @default.
• W165943537 creator A5003035861 @default.
• W165943537 creator A5004992055 @default.
• W165943537 creator A5015736649 @default.
• W165943537 creator A5045774930 @default.
• W165943537 creator A5053850680 @default.
• W165943537 creator A5071644759 @default.
• W165943537 creator A5088915917 @default.
• W165943537 date "2013-01-01" @default.
• W165943537 modified "2023-09-26" @default.
• W165943537 title "Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome." @default.
• W165943537 cites W1512569493 @default.
• W165943537 cites W1965158064 @default.
• W165943537 cites W1971387596 @default.
• W165943537 cites W1974385187 @default.
• W165943537 cites W1993339297 @default.
• W165943537 cites W1995084660 @default.
• W165943537 cites W1995795122 @default.
• W165943537 cites W1999578773 @default.
• W165943537 cites W2019454433 @default.
• W165943537 cites W2023223282 @default.
• W165943537 cites W2023483536 @default.
• W165943537 cites W2029207563 @default.
• W165943537 cites W2029939236 @default.
• W165943537 cites W2035964286 @default.
• W165943537 cites W2051022408 @default.
• W165943537 cites W2053620243 @default.
• W165943537 cites W2061814235 @default.
• W165943537 cites W2064531916 @default.
• W165943537 cites W2067314229 @default.
• W165943537 cites W2079309822 @default.
• W165943537 cites W2080259979 @default.
• W165943537 cites W2081406086 @default.
• W165943537 cites W2109981682 @default.
• W165943537 cites W2124472991 @default.
• W165943537 cites W2146392061 @default.
• W165943537 cites W2162677632 @default.
• W165943537 cites W2167385753 @default.
• W165943537 cites W2171113939 @default.
• W165943537 cites W2217333307 @default.
• W165943537 cites W2383541273 @default.
• W165943537 doi "https://doi.org/10.3290/j.ohpd.a30172" @default.
• W165943537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23878841" @default.
• W165943537 hasPublicationYear "2013" @default.
• W165943537 type Work @default.
• W165943537 sameAs 165943537 @default.
• W165943537 citedByCount "14" @default.
• W165943537 countsByYear W1659435372013 @default.
• W165943537 countsByYear W1659435372015 @default.
• W165943537 countsByYear W1659435372016 @default.
• W165943537 countsByYear W1659435372017 @default.
• W165943537 countsByYear W1659435372019 @default.
• W165943537 countsByYear W1659435372021 @default.
• W165943537 countsByYear W1659435372023 @default.
• W165943537 crossrefType "journal-article" @default.
• W165943537 hasAuthorship W165943537A5003035861 @default.
• W165943537 hasAuthorship W165943537A5004992055 @default.
• W165943537 hasAuthorship W165943537A5015736649 @default.
• W165943537 hasAuthorship W165943537A5045774930 @default.
• W165943537 hasAuthorship W165943537A5053850680 @default.
• W165943537 hasAuthorship W165943537A5071644759 @default.
• W165943537 hasAuthorship W165943537A5088915917 @default.
• W165943537 hasConcept C126322002 @default.
• W165943537 hasConcept C159110408 @default.
• W165943537 hasConcept C159654299 @default.
• W165943537 hasConcept C170286685 @default.
• W165943537 hasConcept C203014093 @default.
• W165943537 hasConcept C2777706064 @default.
• W165943537 hasConcept C2778453870 @default.
• W165943537 hasConcept C2778674544 @default.
• W165943537 hasConcept C2779123688 @default.
• W165943537 hasConcept C2779134260 @default.
• W165943537 hasConcept C2779951463 @default.
• W165943537 hasConcept C2780648854 @default.
• W165943537 hasConcept C3008058167 @default.
• W165943537 hasConcept C504460877 @default.
• W165943537 hasConcept C524204448 @default.
• W165943537 hasConcept C71924100 @default.
• W165943537 hasConcept C90924648 @default.
• W165943537 hasConceptScore W165943537C126322002 @default.
• W165943537 hasConceptScore W165943537C159110408 @default.
• W165943537 hasConceptScore W165943537C159654299 @default.
• W165943537 hasConceptScore W165943537C170286685 @default.
• W165943537 hasConceptScore W165943537C203014093 @default.
• W165943537 hasConceptScore W165943537C2777706064 @default.
• W165943537 hasConceptScore W165943537C2778453870 @default.
• W165943537 hasConceptScore W165943537C2778674544 @default.
• W165943537 hasConceptScore W165943537C2779123688 @default.
• W165943537 hasConceptScore W165943537C2779134260 @default.
• W165943537 hasConceptScore W165943537C2779951463 @default.
• W165943537 hasConceptScore W165943537C2780648854 @default.
• W165943537 hasConceptScore W165943537C3008058167 @default.
• W165943537 hasConceptScore W165943537C504460877 @default.
• W165943537 hasConceptScore W165943537C524204448 @default.
• W165943537 hasConceptScore W165943537C71924100 @default.
• W165943537 hasConceptScore W165943537C90924648 @default.
• W165943537 hasIssue "3" @default.

• next